4.90 USD
▲+0.04+1.45%
盘后 4.85 +0.41%
2026-08-03
市值
$66.00M
市盈率
—
EPS
-4.24
股息率
—
52 周区间
3.16 – 11.89
成交量
233.77K
Beta
-0.91
目标价
23.00
52W 低 3.1652W 高 11.89
价格走势
公司简介
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical...